Gossamer Bio's Seralutinib shows promise for PAH and PH-ILD treatment. The main event comes with its topline results in Q4 ...

The table below is a review of notable updates that occurred in January 2025 for investigational products in development.

The HYPERION study will be stopped early due to positive efficacy data from across the sotatercept clinical program.

Gazyva/Gazyvaro (obinutuzumab) was found to significantly improve complete renal response in lupus nephritis patients, reinforcing its potential as an effective treatment option while also allowing ...